Podcasts about cancer biology

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. Rebecca Whelan, an associate professor of chemistry at the University of Kansas and member of KU Cancer Center's Cancer Biology research program. The discussion focuses on the limitations of the CA125 blood test for ovarian cancer detection and Dr. Whelan's groundbreaking research, which reveals new insights into the structure of the CA125 protein. Dr. Whelan explains how new DNA sequencing technologies and artificial intelligence, specifically the Alpha Fold program, have helped her team improve the understanding and detection of ovarian cancer. Additionally, Dr. Whelan talks about collaborative efforts to identify new biomarkers for early diagnosis of ovarian cancer and shares advice for young scientists interested in making a difference in medicine through chemistry. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about Dr. Whelan's research into CA125 Learn more about ovarian cancer  Read about ovarian cancer screening and diagnosis at KU Cancer Center Learn more about Dr. Rebecca Whelan

Eric Roeland, MD, FAAHPM, FASC, Associate Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine, OHSUMolly Thomas, MD, PhD, Assistant Professor of Medicine, Division of Gastroenterology & Hepatology, Assistant Professor of Cell, Developmental & Cancer Biology, School of Medicine, OHSUCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: https://forms.office.com/r/j8tvnSw5cd (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee Disclosure: The planning committee and have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. Faculty Disclosure: Eric Roeland, MD has indicated relevant financial relationships with ACCME-defined ineligible companies: Scientific Advisory Board (Napo Pharmaceuticals); Expert Witness (Heron Pharmaceuticals); Research (Pfizer). All others in control of content have indicated no relevant financial relationship with an ACCME-defined commercial interest. All clinical content presented is evidence-based and unbiased. All financial relationships have been mitigated.Original Date: May 6, 2025End Date: May 6, 2026

Eric Roeland, MD, FAAHPM, FASC, Associate Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine, OHSUMolly Thomas, MD, PhD, Assistant Professor of Medicine, Division of Gastroenterology & Hepatology, Assistant Professor of Cell, Developmental & Cancer Biology, School of Medicine, OHSUCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: https://forms.office.com/r/j8tvnSw5cd (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee Disclosure: The planning committee and have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. Faculty Disclosure: Eric Roeland, MD has indicated relevant financial relationships with ACCME-defined ineligible companies: Scientific Advisory Board (Napo Pharmaceuticals); Expert Witness (Heron Pharmaceuticals); Research (Pfizer). All others in control of content have indicated no relevant financial relationship with an ACCME-defined commercial interest. All clinical content presented is evidence-based and unbiased. All financial relationships have been mitigated.Original Date: May 6, 2025End Date: May 6, 2026

Send us a textShort Summary: Cancer's metabolic roots with Dr. Thomas Seyfried.About the guest: Thomas Seyfried, PhD is a professor of biology at Boston College. He has researched cancer metabolism, epilepsy, and lipid biochemistry for over 40 years.Note: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Transcript and other information on Substack.Episode Summary: Dr. Thomas Seyfried discusses the mitochondrial metabolic theory of cancer, challenging the dominant somatic mutation theory. He explores how cancer cells rely on fermentation due to defective oxidative phosphorylation, drawing on Otto Warburg's work. Seyfried explains how ketogenic diets and nutritional ketosis can starve cancer cells by limiting glucose and glutamine, while sharing evidence from nuclear transfer experiments and clinical studies. The conversation also covers environmental factors driving cancer and the importance of metabolic flexibility for prevention.Key Takeaways:Cancer is characterized by dysregulated cell growth, but Seyfried argues it stems from mitochondrial dysfunction, not just genetic mutations.Cancer cells ferment glucose & glutamine, unable to use fatty acids or ketones, making ketogenic diets a potential therapeutic tool.Nuclear transfer experiments show cancer traits reside in the cytoplasm, not the nucleus, challenging the somatic mutation theory.Environmental factors like processed foods, stress, and poor sleep disrupt mitochondrial function, increasing cancer risk.Seyfried's glucose-ketone index helps monitor metabolic states to manage cancer & chronic diseases.Cancer rates are rising in younger people, possibly due to obesity, inflammation, and environmental toxins.Metabolic flexibility, cycling between ketosis and carb-based states, may mimic ancestral patterns and reduce chronic disease risk.Related episode:M&M #215: Cancer Metabolism: Sugar, Fructose, Lipids & Fasting | Gary PattiSupport the showAll episodes, show notes, transcripts, etc. at the M&M Substack Affiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Readwise: Organize and share what you read. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. For all the ways you can support my efforts

(2:40) - Cancer-on-a-chip technology advances our understanding of how cancer operatesThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn more about the role of field programmable gate arrays (FPGAs) in the medical world! Become a founding reader of our newsletter: http://read.thenextbyte.com/ As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.

Dr. Dedi Meiri is an Associate Professor at the Technion Institute where he heads the Laboratory of Cancer Biology and Cannabinoid Research. The lab investigates the vast therapeutic potential of secondary metabolites from cannabis and other herbs, algae, and psychedelic mushrooms; and reveals how these naturally occurring metabolites affect various types of cancer, inflammatory diseases, and disorders of the nervous system Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees that seek to advance the fundamental understanding of optimal cannabis and other psychedelic plant usage and curtailing adverse effects. At CannMed 25, Dedi will present "Cannabis as a Therapy Across Diverse Cancer Types: Milestones and Insights from a Decade of Research", which will discuss his lab's work investigating whether Cannabis can serve as a primary pharmaceutical treatment for cancer. We discuss: The wide range of clinical applications for cannabis medicine, including cancer, epilepsy, sleep disorders, Alzheimer's, and women's health issues like endometriosis. How cannabis' entourage effect challenges the traditional one-drug-one-target model. How many powerful cannabinoids are overlooked by standard lab testing methods—even though they exist in significant quantities and show therapeutic potential. Israel's Medical Cannabis Model, which treats cannabis like a pharmaceutical, with prescriptions, clinical oversight, and growing physician acceptance. The goal is to provide evidence-based, accurate treatments that tailor cannabis therapies to specific health conditions and individual needs. Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more. Learn more at trustedcannanurse.com Additional Resources Dedi Meiri Publications on Google Scholar Dedi Meiri on Linkedin Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Drs. Vijaya Gottumukkala and Nicholas Perry discuss the article “Cancer Biology and the Perioperative Period: Opportunities for Disease Evolution and Challenges for Perioperative Care” published in the April 2025 issue of Anesthesia & Analgesia.

In an effort to bring on great guests to go beyond the narrow realm of fitness and nutrition, Dr Joe Zundell (PhD in Cancer Biology) joins me to talk about: -How strength training reduces cancer risk -How maintaining muscle and bone helps survive cancer treatment -Why the cancer cure suppression conspiracy theory is silly logic -What lifestyle behaviours contribute the greatest risk of developing cancer -The relationship between cancer and obesity -Why there's no one dietary ideology that helps to defeat cancer -and much more 00:15 Meet Dr. Joe Zundell 01:12 Strength Training and Cancer Risk 03:19 Understanding Cachexia 07:42 Cancer Treatment and Quality of Life 09:28 Cancer Complexity and Misconceptions 19:51 Environmental and Lifestyle Factors 26:00 Diet, Obesity, and Cancer Risk 32:03 The Impact of Western Diet on Liver Cancer 33:39 Dietary Advice for Cancer Patients 35:57 Understanding Autophagy and Its Role in Cancer 39:30 The Balance of Immune Response in Cancer Treatment 41:17 Debunking Myths About Cancer and Diet 48:51 The Role of Natural Remedies in Cancer Treatment 51:14 Conclusion and Final Thoughts I've been putting a lot of time and effort into making these new episodes valuable for you. You can help me get these great guests and their knowledge in front of more people by: -Subscribing and checking out more episodes -Sharing on your social media (please tag me - I promise I'll respond) -Sharing with the friend you think of who needs this episode Follow Andrew Coates: Instagram: ⁠⁠⁠⁠⁠⁠⁠@andrewcoatesfitness⁠⁠⁠⁠⁠⁠⁠ Join My Email List: ⁠⁠⁠⁠⁠⁠⁠www.andrewcoatesfitness.com

Osteosarcoma Webinar Series: Alexander Davies, DVM, PhD joins us on OsteoBites to discuss his work which is focused on dynamic tumor-microenvironment signaling cross-talk, signal integration, and the development of 3D organotypic and tissue models to study these interactions using live-cell microscopy techniques. Results from studies in the Davies Lab demonstrate the utility of a novel dynamic live-cell tissue model, the lungSITE model, to quantitatively measure and understand tumor signaling dynamics and behaviors within the context of the lung metastatic niche. Data obtained from this model provided new insights into how spatial position and temporal response influence signaling dynamics, specifically in osteosarcoma lung metastasis, to create intratumoral signaling heterogeneity and consequent single-cell drug response variation. Dr. Alexander Davies graduated with a Ph.D. in Biochemistry and Molecular Biology and a D.V.M., with an interest in comparative oncology, from the University of California, Davis. He then completed a post-doctoral fellowship in cancer biology at Lawrence Berkeley National Laboratory before joining The Ohio State University as faculty in the Department of Veterinary Biosciences. While at OSU he was a member of the Comprehensive Cancer Center and faculty in the Cancer Biology and Cancer Engineering programs. Currently, Dr. Davies is an Assistant Professor at the Knight Cancer Institute within the Division of Oncological Sciences and Cancer Early Detection Advanced Research Center (CEDAR) where his work focuses on dynamic tumor-microenvironment signaling cross-talk, signal integration, and the development of 3D organotypic and tissue models to study these interactions using live-cell microscopy techniques.

As 2024 comes to a close, join EMJ Editor, Evgenia Koutsouki as she counts down the standout moments from the past year in the final instalment of our Highlights series. This special episode revisits the top six podcasts from 2024, showcasing the groundbreaking ideas, innovations, and expert insights that shaped the healthcare landscape. From exploring the genetic mysteries of parasitic infections to pioneering biosensors for gut health, this festive wrap-up celebrates a year of exceptional conversations and transformative research.   Timestamps:     (00:00)-Introduction   (00:56)-Intersection between parasitology and genetics   (05:55)-Learning from individuals with low cholesterol   (09:56)-Continuous glucose monitoring and insulin pumps   (13:43)-Brain-gut behavioural therapy   (18:47)-Biosensors to treat gut inflammatory disorders   (21:59)-Microbiome monitoring  (25:50)-Wrap up    Featured Episodes:  The Fate of the Cell  Innovations in Vascular Medicine: From Bench to Bedside  A Personalised Approach to Diabetes  Gut Instincts: Bridging Psychology and Gastroenterology  Agar Art and Biosensor Breakthroughs  Microbe Monitoring: New Frontiers in Pathogen Surveillance 

Dr. Keith Ellis is a Scientist and Associate Professor of Medicinal Chemistry that is dedicating his time, energy, and talents to helping people recover from Long Covid. Dr. Ellis is using his knowledge, expertise, and experience in medicinal chemistry, pharmacology, and natural products to research the biological mechanisms that cause Long Covid and the potential therapeutic mechanisms that can help people recover. Combining this scientific work with his interest in entrepreneurship, Dr. Ellis has designed and brought to market a custom-formulated natural product supplement to help people recover from Long Covid. In 2023, Dr. Ellis founded Science-Driven Supplements and launched its first product: CircuGuard - a natural, herbal supplement to help people recover from Long Covid microclots. Dr. Ellis and Science-Driven Supplements are committed to creating custom-formulated solutions for people with Long Covid that are safe, inexpensive, accessible for everyone without a doctor's prescription, and available RIGHT NOW. Several more products targeting other underlying biological mechanisms of Long Covid are in the design phase and will be launched in the coming year. In parallel with his Long Covid research and work as Founder of Science-Driven Supplements, Dr. Ellis serves as an Associate Professor of Medicinal Chemistry conducting academic research in early lead discovery in the oncology field and teaching organic and medicinal chemistry to graduate students, professional students, and undergraduates. Dr. Ellis has published academic scholarly work in world-class scientific journals including: the Journal of Natural Products, ACS Medicinal Chemistry Letters, ACS Chemical Biology, Molecular Pharmacology, Oncotarget, Oncogene, Bioorganic & Medicinal Chemistry, and Cancer Biology & Therapy. Career Highlights: Founder - Science-Driven Supplements, LLC - 2023 Faculty PositionsVirginia Commonwealth University, Richmond, VAAssociate Professor of Medicinal Chemistry (with Tenure) - 2018-presentAssistant Professor of Medicinal Chemistry - 2008-2018 Education and Professional TrainingBA Cum Laude (Chemistry) - 1999 - Cornell University, Ithaca, NYPhD (Chemistry) - 2004 - University of Virginia, Charlottesville, VAPost-Doctoral Researcher - 2005-2006 - Department of Medicinal Chemistry, University of Kansas, Lawrence, KSResearch Associate - 2007-2008 - Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN Long Covid Research, Social Media Links, and LinkedIn Profile can be found at www.keithcellisphd.com.

Sarah Blagden, pioneer in experimental oncology, returns to the podcast to discuss cancer prediction and prevention, and the future of cancer vaccines. Timestamps: (00:00)- Introduction (00:35)- The mission of RNA Guardian Ltd (02:02)- mTOR in cancer biology (06:24)- Raising awareness of ovarian cancer (08:32)- A new era of cancer prediction and prevention (11:38)- The future of cancer vaccines (15:58)- Advice to medical students: academia versus medicine (19:42)- Sarah's three wishes for healthcare

“Under normal conditions, EGFR [epidermal growth factor receptor] is in an auto-inhibited state. And it's only when it's needed that it's upregulated. But when you have cancers that there is either a mutation in the EGFR or an overexpression, what you see is a dysregulation of normal cellular processes. So you get overexpression or switching on of prosurvival or antiapoptotic responses,” Rowena “Moe” Schwartz, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the EGFR inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to EGFR inhibitor drugs. Episode Notes  Complete this evaluation for free NCPD.  Oncology Nursing Podcast™ episodes: Pharmacology 101 series Episode 250: Cancer Symptom Management Basics: Dermatologic Complications Episode 226: Patient Education for Next-Generation Sequencing to Guide Cancer Therapy Episode 169: How Biomarker Testing Drives the Use of Targeted Therapies Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Management Strategies for Cutaneous Toxicity From EGFR Inhibitors Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Osimertinib Oncology Drug Reference Sheet: Panitumumab Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (Fourth Edition) ONS courses: ONS Cancer Biology™ ONS/ONCC Chemotherapy Immunotherapy Certificate™ Safe Handling Basics Clinical Journal of Oncology Nursing articles: Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices Medication Adherence Barriers: Development and Retrospective Pilot Test of an Evidence-Based Screening Instrument ONS Guidelines™ for Cancer Treatment–Related Skin Toxicity Nursing Management of Skin Toxicities in Diverse Skin Tones ONS Bispecific Antibody Video ONS Learning Libraries: Genomics and Precision Oncology Oral Anticancer Medication Oral Chemotherapy Education Sheets Seminars in Cancer Biology article: EGFR signaling pathway as therapeutic target in human cancers To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “It wasn't until 2004 that the mutations affecting the tyrosine kinase domain of epidermal growth factor receptor was linked to the responses that were seen in gefitinib. And that's when we really started to understand the way that this was targeting certain patients' cancers. So that led to the phase three study. People may remember the IPASS study that demonstrated that when patients had an activating mutation of EGFR, that that was a really good biomarker that selected out patients that would respond to therapy.” TS 2:58 “The new player on the market is the bispecific. … This was a bispecific that was developed to hit two different targets. The one target is EGFR. The second target was MET. And the reason MET was targeted is because when you have patients who are on EGFR tyrosine kinase inhibitors, they do so well. But over time, resistance develops. And one of the mechanisms that are thought to be important for resistance is that MET pathway. So it was a development of a bispecific antibody that hit two different targets, EGFR and MET, hoping that you would get less resistance.” TS 7:12 “The other thing that I see with these agents is seeing them combined with chemotherapy. For a long time, it was these drugs were used as the single approach to someone with non-small cell lung cancer who had an EGFR mutation, and they did well. But I think we're starting to see that because resistance does develop, that there may be roles for combination with chemotherapy, and you're seeing that in terms of drug approval.” TS 19:10 “I think that people that don't work in the clinic, say, with non-small cell lung cancer—they think of these as a group and don't realize the uniqueness of specific agents, what mutations that they hit that affected those that penetrate into the [central nervous system], the drug interactions that are specific for certain agents. So I think that's one of the common misconceptions.” TS 22:02 “The education, because it evolves so rapidly, is to realize that what you know, if it's from a year ago, may not be the full picture. And so again, I'm going to call out ONS for the phenomenal resources on the Genomics and Precision Oncology Learning Library to help providers learn. And that is updated, and it is readily available. I think it is phenomenal, and I think it helps people build on their basic understanding of any of these types of therapy, including EGFR inhibitors.” TS 23:24

University of Kentucky Markey Cancer Center expert Nathan Vanderford, Ph.D., recently contributed to a critical national discussion on sustaining and supporting the cancer workforce. As he explains in this week's Dr. Greg Davis on Medicine, Vanderford, an associate professor in the UK College of Medicine's Department of Toxicology and Cancer Biology, director of Markey Cancer Center's Appalachian Career Training in Oncology Program and assistant director of Markey's Pathway Programs and Student Success, addressed challenges faced by early-career researchers, issues of diversity in cancer research training and opportunities for supporting researchers' career paths.

Join us for a conversation with Dr. Raghu Kalluri, a leading figure in cancer biology, who serves as the Chair of the Department of Cancer Biology at MD Anderson Cancer Center. With over 300 publications, multiple successful biotech ventures, and groundbreaking work in exosome research, Dr. Kalluri discusses the intricate relationship between science, medicine, and industry, his career path from researcher to entrepreneur, and his exciting vision for using innovation to transform cancer care.

"What are the things that cause cancer in people? Can we prevent cancer?" These are the questions Assistant Professor Daniel Hollern is asking in his research at Salk. From blending spices and vinegar on his kitchen floor growing up in Michigan to blending computational biology and immunology on the lab bench in San Diego, learn about Hollern's life and scientific journey in this episode of "Beyond Lab Walls."

The New Student Pharmacist Podcast Experience- Exploration of Cancer Biology and Research --- Note: The views of this podcast represent those of my guest(s) and I. Note: Purpose of these episodes- not at all, for advice or medical suggestions. These are aimed to provide support for peer pharmacists in training in educational and intellectually stimulating ways. Again, these are not at all for medical advice, or for medical suggestions. Please see your local state and board-certified physician, PA or NP, and pharmacist for medical advice and suggestions.   Some content produced involved the use of A.I. .

Stjepan Uldrijan leads the Cancer Biology research group at the Department of Biology, Faculty of Medicine. The group's research centers on molecular mechanisms that regulate cellular signaling pathways driving malignant melanoma. They also investigate how tumor cells respond to stress conditions and are working to identify new targeted therapy options for melanoma. Stjepan Uldrijan was awarded the InGA Accelerate grant in 2022 and 2024 for projects aiming to develop new small-molecule compounds targeting cancer growth.

In this episode, Dr. Stephanie and Dr. Joe debunk common cancer myths while highlighting the importance of a nutrient-rich diet. Learn about the relationship between fibre consumption and cancer, the benefits and misconceptions surrounding coffee, and the impact of gut health on cancer. Whether you're interested in the evolutionary aspects of cell biology or practical dietary strategies to support cancer treatment, this episode offers actionable insights for maintaining a healthy lifestyle and reducing cancer risks.Episode overview:0:00 Intro/Teaser03:40 Exploring the Nuances of Cancer13:36 Understanding Cancer19:14 Genetic Mutations and Cancer Risks33:00 Alcohol Metabolism and Cancer Risks41:54 Cancer Cell Metabolism and Dietary Interventions49:12 Dietary Interventions in Cancer Treatment1:00:32 Exercise and Immune System Function1:04:14 Nutrient-Rich Diet and Cancer Prevention1:11:45 Coffee Consumption and Cancer Risk1:15:40 Debunking Common Cancer MythsResources mentioned in this episode: https://drstephanieestima.com/podcasts/cancer-myths-realities-preventative-measures/Bio:Dr. Joe Zundell received his PhD in Cancer Biology from the Wistar Institute and The University of the Sciences in Philadelphia, PA. USA. Through over 10 years performing lab work, Joe specializes in understanding the metabolic, epigenetic, and genetic contributions for cancers. Currently, he works within the private sector at a biotech company looking to advance targeted radiopharmaceuticals to better treat solid cancers. In his free time, he educates the public on social media about the complexities of cancer biology and how people can reduce their risks for developing cancers.We are grateful to our sponsors:EQUIP collagenYou can use this grass-fed collagen daily, to take care of your hair, skin, nails, joints, and gut after resistance training workouts, or you can even bake with it because it tastes like dessert, not beef. Go to https://equipfoods.com/better and use the code BETTER for 20% off.TIMELINEFeeling tired and having no energy does not have to be your fate. Mitopure is a supplement and skin health line that helps improve energy at the level of the mitochondria so that you can continue to engage in the activities you love. Go to https://timelinenutrition.com/better and use code BETTER to get 10% off your orderAPOLLOThe Apollo wearable supports women's cycle and changing bodies by supporting the circadian and infradian rhythms so you can give your body what it needs when you need it — more energy, relaxation, focus, sleep, or calm. Go to https://apolloneuro.com/DRSTEPHANIE and use code DRSTEPHANIE for 15% off your order.

Kevin Haigis, PhD, Cancer Biology, Chief Scientific Officer, Dana-Farber  Kevin M. Haigis, PhD, joined Dana-Farber as Chief Scientific Officer in 2020. Prior to assuming this role, Dr. Haigis was Director of Cancer Genetics at Beth Israel Deaconess Cancer Center. Dr. Haigis received his PhD in genetics from the University of Wisconsin-Madison and did post-doctoral work at the Massachusetts Institute of Technology, where he was a Robert Black Fellow of the Damon Runyon Cancer Research Foundation. Dr. Haigis has a long-standing interest in intestinal biology and the molecular pathogenesis of colorectal cancer. His laboratory combines computational and informatic approaches with experimental approaches in genetically engineered mice to study the relationship among Ras oncogene signaling, colorectal cancer, and inflammation.

Hear from Barbara Ackerman, 72, lung cancer, Plymouth, with Pasi Jänne, MD, PhD, Senior Vice President for Translational Medicine, Dana-Farber Craig Bunnell, MD, Chief Medical Officer, Dana-Farber Kevin Haigis, PhD, Cancer Biology, Chief Scientific Officer, Dana-Farber  

Content Warning: This one is juicy

SpeakerStuart Buck is the Executive Director of the Good Science Project, and a Senior Advisor at the Social Science Research Council. Formerly, he was the Vice President of Research at Arnold Ventures. His efforts to improve research transparency and reproducibility have been featured in Wired, New York Times, The Atlantic, Slate, The Economist, and more. He has given advice to DARPA, IARPA (the CIA's research arm), the Department of Veterans Affairs, and the White House Social and Behavioral Sciences Team on rigorous research processes, as well as publishing in top journals (such as Science and BMJ) on how to make research more accurate.Session SummaryWorking in the field of meta-science, Stuart cares deeply about who gets funding and how, the engulfment of bureaucracy for researchers, everywhere, how we can fund more innovative science, ensuring results are reproducible and true, and much more. Among many things, he has funded renowned work showing that scientific research is often irreproducible, including the Reproducibility Projects in Psychology and Cancer Biology.Full transcript, list of resources, and art piece: https://www.existentialhope.com/podcastsExistential Hope was created to collect positive and possible scenarios for the future so that we can have more people commit to creating a brighter future, and to begin mapping out the main developments and challenges that need to be navigated to reach it. Existential Hope is a Foresight Institute project.Hosted by Allison Duettmann and Beatrice ErkersFollow Us: Twitter | Facebook | LinkedIn | Existential Hope InstagramExplore every word spoken on this podcast through Fathom.fm. Hosted on Acast. See acast.com/privacy for more information.

Laura Mainz is a postdoctoral researcher in the lab of Professor Jan Karlseder. Always curious about the human body, her father's cancer diagnosis inspired a career in cancer biology. In this episode, we learn about Mainz's journey from Germany to California, the science of stopping cancer before it starts, and how researchers cope with such emotionally draining lab work.

In this thought-provoking podcast episode, we challenge traditional perspectives on the biology of cancer. We question the commonly held belief that cancer is solely a genetic disorder and explore the complex connotations of medical terminology. Going upstream, we delve deeper into understanding cancer beyond genetic dysfunctions, challenging the assumption of unregulated cell growth. We question the traditional methods of studying cells under a microscope and encourage critical thinking in comprehending complex phenomena. The episode takes a critical look at the cellular theory, raising doubts about the belief that all tissues are made up of cells. We challenge the existence of organelles and highlight the limitations of visual proof in living tissue. Our discussion focuses on the abnormal characteristics of cancer cells and their relationship to waste accumulation. We explore the therapeutic response of cancer to emotional, physical, and environmental toxicity and emphasize the need to eliminate toxins and adopt a healthier lifestyle. Challenging prevailing scientific understanding in genetics, we question the stability of the genome in different tissues and the relationship between genes and proteins. We delve into the pH levels of the cytoplasm and nucleus, highlighting their differences and the barrier of the nuclear membrane. We raise questions about mRNA transport and question the authenticity of DNA folding into chromosomes and the double helix structure. Our conversation challenges the credibility of scientific establishments and raises awareness about the impact of environmental and consciousness poisons. We discuss the relationship between cancer and the accumulation of toxic materials in the body, emphasizing the importance of holistic alternative cancer treatments. We emphasize personal responsibility for health choices and challenge the victim mentality, encouraging listeners to recognize their power in shaping their own well-being. The impact of thoughts and mindset on the body is highlighted, as well as the importance of listening to the messages our bodies send us. We challenge the limitations and drawbacks of traditional cancer treatments and advocate for a more holistic approach. Dr. Tom Cowan shares insights on the new biology of cancer and highlights the unique properties of white blood cells. The new Biology Clinic offers treatment based on this perspective, recognizing the limitations of traditional disease-curing methods. Join us in this episode as we challenge conventional understanding of cancer biology, encourage critical thinking, and explore diverse perspectives on cancer, genetics, cellular theory, toxicity, and personal responsibility for health. - Cancer biology and challenging medical terminology- Questioning the traditional view of cancer as solely genetic- Going upstream to understand cancer at a deeper level- Challenging the assumptions about cancer cell growth and behavior- The importance of holistic approaches to cancer treatment----Dr. Tom Cowen's website: https://drtomcowan.com/----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 ---- Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. For more information about products and services discussed in this podcast, please visit www.integrativecancersolutions.com. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com.

When I think of today's guest, Tania Jolley, the words that come to mind include self-belief, intelligence, tenacity, courage, and determination. She is an extraordinary woman who wears many hats - innovator, entrepreneur, wife, mother, and a fierce player in the beauty industry with her groundbreaking product, Lashes of Change. In today's episode I chat with my friend and find inspiration throughout her life and as she makes a positive impact on the world. Listen in as we talk about: Her early life with an undetected hearing difficulty which didn't stop her from streaking ahead. How she is a survivor, having battled breast cancer in 2017. This challenging journey has fuelled her philanthropic mission, with her product aiming to address both medical and environmental issues. Her childhood and the challenging moments of her 20s have shaped who she is today. Her character growth as she navigated through life's ups and downs while remaining focused on her goals. Sharing difficult moments may not be easy, but it allows us to connect with others, offer help and support, and feel less alone. Tania is deeply committed to leaving a positive impact on the world and aims to divert over 1 million mascaras from ending up in landfills (where they currently all end up). She also has a strong desire to leave a lasting legacy of a world free of breast cancer. To achieve this goal, 25% of all profits from Lashes of Change directly support the researchers at the Centre for Cancer Biology in Adelaide who are conducting leading research in breast cancer treatment. If you want to join Tania's movement, she has generously offered free shipping until the end of April for all listeners who purchase over $75 worth of products from Lashes of Change https://lashesofchange.com/. Just enter the code JOCLARK at checkout on her website.   You can also find me on Instagram – https://www.instagram.com/joclarkcoaching/ and Private Facebook Group – https://www.facebook.com/groups/womenswellnesscollective1.   Here's to redefining midlife and making our next half of life even better than the first. 

Mariana Stern, PhD is a professor of clinical population and public health sciences and urology, and the Ira Goodman Chair in Cancer Research. Stern is co-lead of the CoGENES program along with Lourdes Baezconde Garbanati, and associate director for population science at USC Norris Comprehensive Cancer Center. Stern obtained her undergraduate training in Biology at the University of Buenos Aires, School of Sciences, in Argentina with a focus on molecular and evolutionary genetics. She obtained her PhD in Cancer Biology at the University of Texas-MD Anderson Cancer Center and pursued postdoctoral training in molecular epidemiology at the National Institutes of Environmental Health Sciences, National Institutes of Health. At USC, she is currently Director for the MS in Applied Biostatistics and Epidemiology program and teaches undergraduates and graduate students. Her overall research interests cut across the following main themes: diet and cancer, clinical epidemiology of prostate cancer, and cancer health disparities in Latino populations.Learn more about this episode and others at keck.usc.edu/pphs/podcastStay in the loop - subscribe to the Preventive Dose newsletter for monthly news straight to your inbox.Follow us on social - find us at @uscpphs Instagram TikTok Facebook LinkedIn X YouTube

In a new Voices of UMass Chan podcast, Marcus Ruscetti, PhD, assistant professor of molecular, cell & cancer biology, shares his journey into the field of science. Dr. Ruscetti's parents, Frank and Sandy Ruscetti, are retired scientists from the National Cancer Institute, and he said he initially tried not to follow in their footsteps. Learn more about his work: https://www.umassmed.edu/ruscettilab/

"This is a quiet an d friendly community and people look out for each other” those are the words of Afshin Samali, a former refugee who has been in Ireland for 38 years following the arson attack on a Galway hotel earmarked for asylum seekers. Speaking to Newstalk Breakfast was Afshin is a Professor of Cancer Biology at University of Galway,

With 477,000 newly infected Lyme patients every year, and 40% of those are pediatric, Lyme patients need a working diagnostic and effective treatment.  New developments out of Duke University, carried forward from the late Oncologist and Lyme patient, Dr. Neil Spector, shows promise to solve every Lyme patients nightmare for accurate testing and an effective treatment.  Inspired by research that targets cancer tumors, these new findings in Lyme could also lead to novel R&D strategies for other diseases.PORTOLA VALLEY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced the development of a potential new drug, HS-291, that targets and destroys Borrelia burgdorferi, the bacterium that causes Lyme disease. Published in the peer-reviewed journal Cell Chemical Biology, this laboratory study represents a novel paradigm shift for anti-microbial treatment research as it is the first to target and inhibit Borrelia burgdorferi HtpG (high temperature protein G), a specific type of enzyme within the bacteria that causes Lyme disease— a condition affecting nearly 500,000 new patients annually. The research was conducted at Duke University School of Medicine, with collaboration from University of North Carolina, Tulane University, and Stanford University, and HS-291 is currently in preclinical stage testing at UC Davis.“As Lyme disease is currently treated with broad spectrum antibiotics and there are no targeted treatments, we are particularly excited about this discovery, and hopeful that our novel Lyme disease therapeutic HS-291 will specifically destroy the Lyme bacterium without off-target effects or antibiotic resistance,” said Timothy Haystead, PhD, professor of Pharmacology and Cancer Biology, Duke University School of Medicine, Bay Area Lyme Foundation grantee, and co-lead author. “This research has been an incredible opportunity to leverage knowledge from oncology to Lyme disease in order to design an investigational therapeutic that could one day benefit hundreds of thousands of patients with Lyme.”This new discovery has implications beyond Lyme disease as it demonstrates that using the drug HS-291 to deliver cellular toxins to HtpG, a type of non-essential enzyme that assists the folding or unfolding of large and complex proteins, greatly expands what can be considered druggable within any pathogen and opens a whole new area of infectious disease research.This work will require around a $10mm total investment to bring to the public.  We are bringing this presentation to you today from Dr. Tim Haystead to show you the power of this work and why it's important to join us to support ensuring Dr Spector's mission is successful through donations.  Every amount helps, so please donate at www.TXLymeAlliance.org/donate and subscribe to our channel to support our efforts to open access to care for Lyme patients. SHARE this to help us find solutions for those suffering from Lyme disease.#LymeDisease #Dukeuniversity #NeilSpector #Lymetreatment #LymeresearchSupport the show

Dr. Wenbo Yu, Stanley from the Centre for Cancer Biology, SA Pathology and University of South Australia details a #research perspective he co-authored that was #published by Aging (Aging-US) in Volume 15, Issue 17, entitled, “A Poisson distribution-based general model of cancer rates and a cancer risk-dependent theory of aging.” #author #authorinterview #interview #aging #cancer #entropy #poisson #perspective #openaccess #openscience #peerreview #journal #publication #meded #agingshort #video DOI - https://doi.org/10.18632/aging.205016 Corresponding author - Wenbo Yu - stanley.yu@sa.gov.au Video interview - https://www.youtube.com/watch?v=1n7puuJrido Transcription - https://aging-us.net/2023/10/23/behind-the-study-poisson-distribution-based-model-of-cancer-rates-cancer-risk-dependent-theory-of-aging/ Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205016 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cancer incidence model, poisson distribution, entropy About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY- October 4, 2023 – A new review paper was published in Oncotarget's Volume 14 on September 28, 2023, entitled, “UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology.” UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, researchers Meghan J. Price, Annee D. Nguyen, Jovita K. Byemerwa, Jasmine Flowers, César D. Baëta, and C. Rory Goodwin from Johns Hopkins Hospital, Duke University, Stanford University, Duke Center for Brain and Spine Metastasis, and Duke Cancer Institute classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. “As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.” DOI - https://doi.org/10.18632/oncotarget.28514 Correspondence to - C. Rory Goodwin - rory.goodwin@duke.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28514 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, UDP-6 glucose dehydrogenase, UGDH, oncology, cancer biology About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Dr. Shannon Westin and her guest, Dr. Andreana Holowatyj, discuss the paper "Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer," recently published in JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hello, everyone, and welcome to another episode of the JCO After Hours podcast, the podcast where we get in-depth on manuscripts and interesting papers that are published in the Journal of Clinical Oncology. I am your host, Shannon Westin, and it's my pleasure to serve not only as a GYN Oncologist but as an Associate Editor for Social Media for the JCO. And as always, I'm super excited about the paper that we're going to discuss today. This is “Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer.” This has been published in the JCO. And I am so excited to be accompanied by the last author, Dr. Andreana Holowatyj, who is an Assistant Professor of Medicine and Cancer Biology at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center.  Welcome. Dr. Andreana Holowatyj: Thank you, Dr. Westin, for having me. I'm really excited to get to talk about this paper. Dr. Shannon Westin: So are we. And please note that we do not have any conflicts of interest with this work.  So let's get started. First, early-onset colorectal cancer is any colorectal cancer diagnosed before age 50. So I just wanted to level set. Can you give us a bit of background on the incidence of early-onset colorectal cancer? Dr. Andreana Holowatyj: Sure. All of the attention recently has been drawn to the fact that in contrast to incidence of colorectal cancer decreasing among adults over age 50, we've seen over the last several decades, this uptick—alarming uptick, in fact, in colorectal cancers among individuals diagnosed younger than age 50 years, or, as you point out, we call early-onset colorectal cancer, largely with reasons that are unexplained overall, which has drawn a lot of concern and attention as to what are the factors driving this marked increase in early-onset colorectal cancer both in the United States and globally. Dr. Shannon Westin: And what do we know about the burden of early-onset colorectal cancer across different racial and ethnic groups? Are there disparities in survival like we've seen in some of the other cancer types? Dr. Andreana Holowatyj: Yeah. So recently, a paper published demonstrating this greater shift towards early-onset colorectal cancer, where now we're seeing approximately 1 in every 8 adults with colorectal cancer being diagnosed under age 50. Add to that prior studies have shown that the proportion of early-onset colorectal cancer cases or incidence is actually higher among individuals who identify as non-White compared to those who identify as non-Hispanic White. We previously published in JCO a paper that assessed disparities in survival among early-onset colorectal cancer patients and strikingly found that individuals who identify as non-Hispanic Black had poorer survival compared with non-Hispanic Whites, both in colon and rectal tumors, specifically for young individuals. However, and of striking interest, we did not see these survival disparities between Whites and individuals who identify as Hispanic, which further led us to question what may be some of the biological, environmental, and other factors that may actually be driving some of these disparities by race and ethnicity, both in incidence but also in outcomes. Dr. Shannon Westin: So that kind of brings us to this study. Will you walk us through what the objective of this study was? Dr. Andreana Holowatyj: Yeah. So the underlying question really is what could be the role of germline genetic features or germline predisposition in early-onset colorectal cancer disparities? We know from prior studies published in JCO and other journals that about 14%-25% of early-onset colorectal cancer cases have a germline predisposition. However, these populations have been of limited size and, more importantly, of limited diversity. So we really wanted to tackle that question to understand what is the prevalence and spectrum of germline genetic features in early-onset colorectal cancer by race and ethnicity. Are there differences? Where do these differences lie? And what can this information really tell us in better understanding the early-onset colorectal cancer burden? Dr. Shannon Westin: Well, now, well, just talk us through the design that you employed to achieve these objectives. Dr. Andreana Holowatyj: We were fortunate to partner with a nationwide clinical testing laboratory to identify individuals who were between the ages of 15 and 49 years when diagnosed with the first primary colorectal cancer over about a five-year study period. We were able to identify around 4,000, or specifically 3,980 individuals, who identified as non-Hispanic White, non-Hispanic Black, Hispanic/Spanish or Latino, Asian, or Ashkenazi Jewish who had clinical multigene panel testing uniformly for 14 genes that have a known susceptibility to colorectal cancer overall, to really examine the prevalence and spectrum of genetic features across these self-identified racial/ethnic groups.  Dr. Shannon Westin: And what was the overall prevalence of germline mutations in this population? And did it differ kind of overall in the different racial and ethnic groups? Dr. Andreana Holowatyj: Overall, the prevalence of germline genetic features when assessing 14 colorectal cancer susceptibility genes in this population was pretty consistent with prior studies at 12.2%, seeing about 1 in every 8 patients present with germline genetic predisposition. However, when we teased these numbers apart across racial/ethnic groups, what we saw is the prevalence of these germline genetic features ranged from 9.5% in individuals who identified as Asian to 10.3% of individuals who identified as Black, 12.4% as White, 12.7% for individuals who identify as Ashkenazim, all the way up to 14% of individuals who identify as Hispanic within this population. So we saw a wide—a decently wide breadth of prevalence across these racial/ethnic groups overall. Dr. Shannon Westin: And of course, as a gynecologic oncologist, I'm always centering myself and thinking about Lynch Syndrome. So how did the prevalence of mutations in the mismatch repair gene differ between racial and ethnic backgrounds? Dr. Andreana Holowatyj: So really interesting question. Overall, about 7% of individuals in our cohort presented with a pathogenic or likely pathogenic variant in the mismatch repair gene. But what we saw is that the prevalence of Lynch Syndrome varied from 3% or so of Ashkenazim individuals all the way up to 9.9% of Hispanic individuals. We saw that variance in MLH1 strongly differed across racial/ethnic groups, particularly in the Hispanic population, that accounted for some of these differences. Dr. Shannon Westin: And then were there any differences in some of the other germline mutations that you explored? Dr. Andreana Holowatyj: Yeah, we also observed differences in the prevalence of APC mutations, although largely attributable to the p.I1307K variant in Ashkenazim individuals, as well as CHEK2, monoallelic MUTYH, and PTEN. Dr. Shannon Westin: Okay. Interesting. I was intrigued about those findings for the monoallelic MUTYH variants. Do you think we should be potentially doing increased screening in specific populations based on your results? Dr. Andreana Holowatyj: Yeah, so I think to kind of put this into context, most people probably know that biallelic MUTYH variants yield MUTYH-associated adenomatous polyposis and, of course, confer a strong increased risk of colorectal cancer development. In monoallelic carriers of MUTYH variants, there really is limited evidence to guide clinical management, and this is an evolving area. Per NCCN guidelines, unaffected individuals with a monoallelic MUTYH pathogenic variant and a family history of colorectal cancer in a first-degree relative are recommended to get colonoscopy screening every five years beginning at age 40 or 10 years prior to the age of that first-degree relative of colorectal cancer diagnosis.  However, for individuals with a monoallelic MUTYH variant and no known family history of colorectal cancer, it's inconclusive as to whether specialized screening and surveillance are warranted. Current studies conducted in European or predominantly White populations have reported conflicting evidence as to whether there is an increased colorectal cancer risk for carriers of a monolithic MUTYH pathogenic variant. I don't think we're quite there yet to make a conclusive decision on whether increased screening is warranted in the population or not. I think the evidence is leaning towards potentially seeing not a strong increased colorectal cancer risk, but we'll have to wait and see on some additional studies to be conclusive in that area. Dr. Shannon Westin: I was also intrigued—the lack of difference in germline features between Blacks and Whites was stark. I mean, why do you—what do you think might have led to us not seeing a difference there? Dr. Andreana Holowatyj: I think there's potentially two avenues for this. I want to caveat the fact that this could be attributable to a limited sample size. Although we had about over 1,000—just over 1,000 individuals who identified as non-White, there's still potential selection bias in this cohort. However, we have included about a comparable number of individuals who identified Blacks and Hispanics herein, which does raise this question of we see differences in germline genetic features between Whites and Hispanics, but the lack of difference between individuals who identify as White and Black kind of yields possibly two avenues. If germline genetic features do contribute to racial/ethnic differences in early-onset colorectal carcinogenesis and outcomes, then there's a chance that we have not yet identified ancestry-specific variants associated with early-onset colorectal cancer. This has marked implications in the development and equitable design of multigene panel tests.  However, we also know that beyond genetics, the interplay with biology, social determinants of health, and behaviors could also underlie these distinct patterns. We recently demonstrated in a separate paper that we see actually differences in the tumor mutation burden between individuals who identify as Black or White, which is supporting the idea that a distinct tumor biology may be driving early-onset colorectal cancer disparities. And if there are no germline genetic features, then the question is really how does that interplay of the environment—some of these other complex interrelated factors, how could that be driving disparities in early-onset colorectal cancer incidence and outcomes, particularly for individuals who identify as Black? Dr. Shannon Westin: And I guess that kind of leads to my next question. The testing platform that you studied, is it all-inclusive? Are there other mutations that might be relevant, or just we don't know yet? Dr. Andreana Holowatyj: Yeah. So I think one of the advantages of this study is that all individuals had clinical multigene panel testing for the 14 genes that we evaluated overall. However, while that's a strength of the study, it's also a limitation, given that we only queried 14 genes with unknown colorectal cancer susceptibility, which really is a first step, yet a key step, in further studies and supporting further discovery of potential ancestry-specific variants or genes associated specifically with early-onset colorectal cancer predisposition. Dr. Shannon Westin: That makes a lot of sense. And I guess that's the next kind of natural question is so what do we do next, right? Where do we go? How do we move this forward? Dr. Andreana Holowatyj: Yeah. So I think one of the advantages of this approach and being fortunate to partner with the clinical testing laboratory is that the study was nationwide among individuals who, of course, had multigene panel sequencing. But at the same time, we were able to accumulate a sufficient number of cases to be able to study these patterns across population groups. I think the natural next step from multigene panel testing is based upon these findings to move into clinical exome sequencing to be able to not only move towards identifying genetic ancestry, since that's, of course, the biological construct—and I would be remiss if I didn't acknowledge that race and ethnicity is a social construct but was all that was available in the context of this present study—but also will allow us to query the entire exome and understand and dive deeper into some of these questions: variants of uncertain significance and also potential ancestry-specific variants. Dr. Shannon Westin: Well, great. Well, this is super intriguing, and I know this is going to get a lot of excitement and attention from our readership. So I just want to thank you again for taking the time to review this really important paper, “Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer.” Again, I'm Shannon Westin, and I'm just so grateful that everyone came to listen to JCO After Hours. Please do check out our website for other podcasts you might have missed. Have a great one.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Mark Harris and Joe Lynch discuss the rise of exosuits. Mark is the CEO of HeroWear, a wearable technology company focused on developing assistive clothing solutions. About Mark Harris Mark is a driven, serial entrepreneur with an innovator's mindset. At HeroWear, Mark leads a team of amazing engineers, designers, manufacturers, and business experts to launch a line of exosuits that will improve the health, safety, and productivity of workers within the logistics industry. Previously, Mark founded and led Concert Genetics in its mission to connect the Genetic Health Information Network. Mark is deeply involved in the entrepreneurial ecosystem, having advised startup accelerators, investment groups, and early-stage companies in Nashville, and has been recognized as one of Nashville's Forty Under 40 and was awarded as one of 25 Health Care Heroes selected by the Chamber of Commerce for his contributions and leadership in the community. Mark earned three degrees from Vanderbilt University: a BS in Molecular and Cellular Biology, a Ph.D. in Cancer Biology, and an MBA from the Owen Graduate School of Management. About HeroWear HeroWear is a wearable technology company that aims to revolutionize physical labor by developing exoskeleton technology to prevent back pain and improve people's lives. Their focus is on providing comfortable, reliable, and effective protection for working men and women in various industries such as warehouses, manufacturing centers, and construction sites. Founded in 2019, HeroWear introduced their first product, the Apex exosuit, in 2020. Since then, thousands of users at hundreds of customers have experienced the benefits of the suit, allowing them to feel better and work smarter. In 2021, HeroWear embarked on a project to develop the SABER exosuit for the US Army, showcasing their expertise and commitment to innovation. In 2023, HeroWear unveiled the Apex 2, the latest advancement in their back-assist exosuit technology. This new iteration is even more comfortable, user-friendly, and durable, incorporating valuable insights gained from real-world usage of the Apex exosuit. With a strong track record and a dedication to improving the lives of workers, HeroWear continues to lead the way in the field of wearable technology for physical labor. Key Takeaways: The Rise of Exosuits Mark Harris is the CEO of HeroWear, a wearable technology company focused on developing assistive clothing solutions. In the podcast interview, Mark and Joe discuss the rise of exosuits, which is what Mark and the HeroWear team provide to the working men and women in various industries such as warehouses, manufacturing centers, and construction. Their first product, the Apex, is a back-assist exosuit designed to reduce strain on the back. The Apex was developed in collaboration with the Center for Rehabilitation Engineering and Assistive Technology at Vanderbilt University. It is the first exosuit built from the ground up for both men and women. The Apex features a patent-pending dual-mode technology that allows users to easily turn the back assistance on or off. The textile-based design of the Apex is modular, offering over 50 possible combinations for a perfect fit and support. HeroWear also offers the Apex 2, a lightweight back-assist exosuit that focuses on comfort and wearability. The Apex 2 reduces muscle fatigue and strain, providing more energy on the job and a better quality of life outside of work. HeroWear offers an exclusive exo-as-a-service for select companies interested in their technology. They also provide pilot programs and field studies to gather data and equip companies with the information needed to implement exosuit programs. Learn More About The Rise of Exosuits Mark on LinkedIn HeroWear on LinkedIn HeroWear website HeroWear YouTube Channel ROI Calculator Episode Sponsor: Port X Logistics Is Drayage Just Drayage with Brian Kempisty Episode Sponsor: Lean Solutions Group Outsourced Sales and Marketing with Ryan Mann The Logistics of Logistics Podcast If you enjoy the podcast, please leave a positive review, subscribe, and share it with your friends and colleagues. The Logistics of Logistics Podcast: Google, Apple, Castbox, Spotify, Stitcher, PlayerFM, Tunein, Podbean, Owltail, Libsyn, Overcast Check out The Logistics of Logistics on Youtube

When it comes to bladder cancer, African Americans are often diagnosed at an advanced stage, which results in worse outcomes. In this episode, Dr. P and her guests discuss the facts about bladder cancer, its symptoms, and why it frequently is misdiagnosed, especially among women.   Dr. Samuel Washington is Assistant Professor of Urology and holds the Goldberg-Benioff Endowed Professorship in Cancer Biology at the University of San Francisco. He was a 2019 John Quale Travel Fellow at the Bladder Cancer Advocacy Network. Dr. Washington's research has focused on healthcare disparities in medical care, specifically bladder and prostate cancer.Jim Scott is an entrepreneur, business manager, and bladder cancer survivor from the Detroit area. As a volunteer with the Black Men's Cancer Action Council, Mr. Scott encourages men to overcome their reluctance to visit the doctor and urges them to get screened for bladder cancer.

Dr. Claudia Benavente studied Molecular Biotechnology Engineering at Universidad de Chile where her interest in pursuing cancer research first started. To further her studies, she came to the US to pursue a doctoral degree in Cancer Biology at The University of Arizona as a Fulbright scholar. She then moved on as a postdoctoral fellow to St. Jude Children's Research Hospital in Memphis, TN where she became familiar with childhood solid tumors. Professor Benavente is currently an Associate Professor at the Departments of Pharmaceutical Sciences and Developmental and Cell Biology and a member of the Chao Family Comprehensive Cancer Center at the University of California, Irvine. Dr. Benavente's research focuses on understanding how pediatric tumors form to design new ways to treat them. Her research aims to understand how genes are normally controlled in developing tissues and how epigenetic processes are perturbed to facilitate cancers to arise. This information guides her in the development of new therapies. --- What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 

Join us for a chat with the founder of @michalmorrisonskincare as she shares the story behind the creation of the Genesis βSTEM6TM Molecular Serum, which aims to define and lead a new category of biomimetic skincare technology with its proven, proprietary, and patent-pending βSTEM6 molecule. This biotech breakthrough has a mechanism of action validated by 25 years of research in stem cell science and regenerative medicine from the laboratory of Dr. Michael Kahn. The βSTEM6 molecule will be exclusively available in Michal Morrison products. The company was founded by Austin-based entrepreneur Michal Ann Morrison, who previously survived a Traumatic Brain Injury in 2016 and has since become a passionate advocate for people with disabilities. βSTEM6 is a nextgen, patent-pending ‘metamoleculeTM' that restores the self-rejuvenating power of our skin that has diminished over time. The result of over two decades of research in regenerative medicine and recent advances in stem cell science, βSTEM6 uses your biology's inherent potential to extend cell longevity. As the first and only bioserum with βSTEM6, this molecular superpower works with the skin's chemistry to awaken the millions of cells responsible for healthy-looking skin. A formal and independent clinical study was conducted by one of the country's preeminent board-certified dermatologists and President of Dermatology Consulting Services, PLLC, Dr. Zoe Draelos, M.D. The study demonstrated dramatic improvements in the multiple signs of skin aging such as facial lines, wrinkles, loss of elasticity and uneven pigmentation. The inspiration for the development of the company's proprietary and patent-pending intellectual property, the βSTEM6 molecule, was Michal's association with Dr. Fuqiang Ruan, an innovative scientist with a doctorate in Synthetic Organic Chemistry who had previously worked in Dr. Kahn's laboratory. Dr. Michael Kahn is currently Professor of Cancer Biology and Molecular Medicine at the Beckman Research Institute, City of Hope. --- Send in a voice message: https://anchor.fm/skincareanarchy/message Support this podcast: https://anchor.fm/skincareanarchy/support

This week, we're joined by Oliver Maddocks, Co-Founder & Head of Research at Faeth Therapeutics and Professor of Cancer Biology & Metabolism at The University of Glasgow. Oliver is an expert in cancer metabolism and a pioneer in the cancer research space. His work at Faeth is dedicated to using metabolism alongside treatment to fight against cancer. In this context, metabolism refers to more than just how the human body metabolizes food, but how cancer cells metabolize nutrients as well. Through clinical trials, the team at Faeth is blazing trails for our understanding of how diet can have a role in the treatment of cancer - not just prevention. To learn more about Fath Therapeutics and find out if you are eligible to enroll in these groundbreaking clinical trials, visit https://faeththerapeutics.com/. To learn more about Faeth's pancreatic cancer clinical trial specifically, visit https://faeththerapeutics.com/pancreatictrial. To learn more about Project Purple, visit https://www.projectpurple.org/ or follow us on social media at these links: https://www.facebook.com/Run4ProjectPurple https://www.instagram.com/projectpurple/ https://twitter.com/Run4Purple https://www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

After hurting his leg as a sophomore in high school during a school football game in 2010, Ian Lock  went to his pediatrician who saw a dark spot on his leg while examining him. This spot turned out to be Osteosarcoma. Ian went through the usual difficult treatment for this most common form of bone cancer, and fortunately he did not suffer a relapse which so many Osteosarcoma patients do.Ian then decided to become an advocate through the American Cancer Society for Pediatric Cancer while still in high school and then while in college, decided to do research on such pediatric  cancers as Hepatoblastoma, Leukemia , and Osteosarcoma.Ian is now going after his PHD in Molecular Cancer Biology from Duke University and his career path is geared towards in some way helping Pediatric Cancer patients find an easier path to handle their own cancer battles.  

Dr. Caitlyn Barrett has her PHD in Cancer Biology from Vanderbilt University plus her post doctorate from the University of Pittsburgh.  She has taken her education to concentrate on helping many kids who have some form of Pediatric Cancer. On today's podcast, Dr. Barrett will talk about some of the highlights that she has experienced in her prominent roles at Curesearch For Kids Cancer, the Coalition Against Childhood Cancer, and her current role as an Associate Director of the Milken Institute Center For Strategic Philanthropy. 

Dr. Carnahan received his BS in Biology and BS in Psychology from Indiana University, jumped into the industry, working for Eli Lilly in both the US and France, then he came back to academia as a researcher at the Institut Pasteur in Paris, France. He completed his Ph.D. in Cell Biology at Vanderbilt University and his post-doc in the laboratory of Al Reynolds, Ph.D. In 2006, he was appointed as Director of the Vanderbilt Antibody and Protein Resource (VAPR). In addition to directing the VAPR, Dr. Carnahan is an Associate Professor in the Cancer Biology, Faculty director of the Management and Entrepreneurship for Scientists program, a member of the Medical School admissions IAC committee, and is a faculty instructor for both M.D. and Ph.D. training programs. In 2010 he co-founded the Antibody-Technologies Research Group.

Featuring perspectives from Dr Stephanie Lheureux, including the following topics: Prologue: Seminars in Cancer Biology (0:00) Case: A woman in her mid 50s with Stage IVB BRCA wild-type, HR-proficient primary peritoneal cancer — Dana M Chase, MD (10:54) Case: A woman in her mid 70s with recurrent platinum-sensitive peritoneal cancer (Lynch, VUS) and a gBRCA2 mutation— Karim ElSahwi, MD (32:33) Case: A woman in her early 60s with ovarian cancer and prolonged pancytopenia after treatment with a PARP inhibitor — Joseph Martins, MD (38:51) Case: A woman in her mid 60s with platinum-resistant recurrence of BRCA wild-type clear cell ovarian cancer after carboplatin/paclitaxel/bevacizumab and maintenance bevacizumab (homologous recombination deficiency [HRD] negative) — Neil Morganstein, MD (43:21) Case: A woman in her early 60s with multiregimen-recurrent BRCA wild-type, HRD-negative metastatic ovarian cancer — Rahul Gosain, MD (47:44) Case: A woman in her late 60s with recurrent platinum-resistant, BRCA wild-type, HR-proficient ovarian cancer after receiving paclitaxel/tumor treating fields on a clinical trial — Dr Chase (52:07) CME information and select publications

When Erin Stern was a teenager in San Diego, she worked one summer at a camp for Pediatric Cancer patients. Later, she went to Harvard University where she received her PHD in Cancer Biology. While there, she decided to start her own summer camp which she named Camp Casco.  This camp  welcomes children and adolescents ages 7-17 to come for one week during the summer to enjoy all of the activities, meet new friends, and most importantly, be able to spend time having fun and not thinking about all of the protocols that they have to go through while fighting their individual cancer battles.

Gene therapy! The next big thing. But what does it all mean? What are the ethics? Where did it even come from? What in the sweet hell is CRISPR? This week we hop in the time travel machine and head all the way back to that time the fellas are joined by Dr. Graham Dellaire, Professor of Pathology at Dal & Principle Investigator at the Dellaire Lab of Nuclear Structure and Cancer Biology. He drops some fascinating knowledge on all things gene therapy & gene editing! This episode is a nerd's wet dream. Sickboy LIVE in Edmonton Tickets: https://www.eventbrite.ca/e/sickboy-live-in-edmonton-tickets-400700244217 Sickboy LIVE in Vancouver Tickets: https://admitone.com/events/sickboy-podcast-vancouver-8301026 Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

On Episode 31 of Black in Science, I sat down with Dr. Jamaine Davis who currently works as an Assistant Professor in the Department of Biochemistry and Cancer Biology at Meharry Medical College. To open, Dr. Davis discusses his childhood while growing up in Long Island, New York. He then segues into his experience as an undergraduate chemical engineering major at Temple University and Drexel University in Philadelphia, Pennsylvania before discussing his transition into the biomedical research field. After sharing the details of his Ph.D dissertation research in the Department of Biochemistry and Molecular Biophysics at the University of Pennsylvania, Dr. Davis delves into the work he did for both of his postdoctoral fellowships at the National Cancer Institute in Maryland. Following this, Dr. Davis describes the Breast cancer and Alzheimer's structural biology and health disparities research his lab focuses on before disclosing his short term and long term goals. To conclude, Dr. Davis shares his feelings on the importance of seeking help, remaining your authentic self and more. If you've enjoyed listening to Dr. Davis' episode of the podcast and wish to contact him with questions, feel free to reach out via: Email: jdavis@mmc.edu Twitter: @jscdavis

Episode 74 - Harmful Algae Blooms with Dr. Ed LevinDr. Edward Levin is Chief of the Neurobehavioral Research Lab in the Psychiatry Department of Duke University Medical Center. He also has secondary appointments in the Department Pharmacology and Cancer Biology, the Department of Psychological and Brain Sciences, and the Nicholas School of the Environment. His primary project in neurobehavioral toxicology focuses on the cognitive deficits caused by the marine toxins including domoic acid, ciguatera toxin and pfiesteria aka algae blooms. His team has documented evidence that persistent neurobehavioral effects can be caused by pfiesteria and domoic acid exposure as published in, "And the Water's Turned to Blood: In the Rivers and Coastal Waters of America, An Ancient and Deadly Organism, Reawakened By Man-Made Pollution May Become the Ultimate Biological Threat," by Rod Barker. In this episode, we discuss how harmful algae blooms can trigger illness.  Transcript: https://bit.ly/3ygM8HV Find us on Linktree, Facebook, Instagram, Twitter,  TikTok and YoutubeNeed help navigating your mold injury without breaking the bank? Join our low cost education group: patreon.com/exposingmoldPartners:Michael Rubino, The Mold Medic and  Home Cleanse, formerly known as All American Restoration,  is the first and only mold remediation company in the country specializing in remediating mold for people with underlying health conditions or mold sensitivities. They've quickly become the most recommended remediation company  from doctors and mold inspectors nationwide. Pick up your copy of Michael Rubino's book, “The Mold Medic: An Expert's Guide on Mold Remediation, " here: https://amzn.to/3t7wtaUThe Mold Guy performs mold inspections specifically for individuals who require a much higher standard of care owing to complex health concerns like CIRS, Lyme, CFS, Autoimmune issues and more.  Their testing and inspection process supersedes all current industry standards, on purpose, making them thought leaders and disruptors in an industry unwilling to change old and outdated paradigms.  Book your complimentary phone consult here: https://themoldguyinc.com/connectTexas Mold Inspectors has helped establish over 150 mold cases resulting in millions of dollars of damages being awarded back to their clients. They are a true unbiased, third party, mold assessment company that specializes in forensic type mold assessments as well as standard mold assessments. Contact Texas Mold Inspectors The LighthouseHalf-hour moments of comfort and company. Because some days, you just want a hug.Listen on: Apple Podcasts SpotifySupport the show

Alexia Carrillo is a driven mother, wife, coach and podcaster. After receiving a PHD in Cancer Biology and working as a teacher, Alexia felt called to transition to being a work from home mom to spend more time with her son. However, her transition home was not the fairytale she imagined. She began to experience struggles with balance and unmet expectations. Alexia would later create her podcast, Mama With A Calling, to shares her own experiences and help other moms that are also changing their career direction to find balance and peace. We chat about our mutual struggles as achievers and how a desire to achieve can make a work and home life balance difficult, how we can make sure we are prioritizing our family, and we contrast some of the advice Alexia received from non-Christian sources to what she found in the Bible.Show NotesSupport the show

Episode 80: Al Malecha | Girls Love Evidence-Based Wellness Show Notes: On this episode of the Alix Turoff Nutrition podcast, Alix sits down with Al Malecha. Al Malecha is the creator of Girls Love Evidence, an evidence-based health and wellness blog. Girls Love Evidence was born when she became fascinated with how influencers, wellness blogs, and even some health professionals promote health trends that have very little scientific evidence to back them up. As many health trends are targeted towards body insecurities or historically under-researched disease, women and people of color are specifically susceptible to the harm these trends can cause to their health and wallets.  With a Bachelors in Biochemistry and Masters in Cancer Biology, Al uses her love of science, peer-review, and spending too much time on social media to fact-check and explain, with the goal of making high-quality scientific information accessible to all. Outside of writing, Al is a first-year law student with an interest in bioethics and intellectual property, and she spends a lot of time with her dog. Some of the topics we covered in this episode include: What does it mean to be "evidence-based"? Social media and influencer wellness trends How to find quality scientific information if you don't have a science background And more! To learn more about Al, visit her website GirlsLoveEvidence.com or connect with her on instagram (@girlsloveevidence)   Resources: Get the 5 week Flexible Nutrition Starter Kit Apply for Alix's 12 week small group coaching program Apply for Alix's 1:1 coaching program Follow Alix on Instagram  Join Alix's private Facebook group Download your FREE Happy Hour Survival Guide Buy Alix's book on Amazon Shop my favorite products on Amazon Contact Alix via email Be sure you're subscribed to this podcast to automatically receive your episodes!!!    If you enjoyed today's episode, I'd love it if you would take a minute to leave a rating and review! Subscribe to The Alix Turoff Nutrition Podcast Discount Codes: Built Bar: Use the code ALIX for 10% off your order Legion Athletics: Use the code Alix for 20% off your order  

Host: Dr. Jennifer Hunter, Assistant Director for Family and Consumer Sciences Extension, University of Kentucky  Guests: Dr. Nathan Vanderford, UK College of Medicine, Department of Toxicology and Cancer Biology and Markey Cancer Center, Karlee Compton and Michael Buoncristiani, ACTION Program student participants   Cancer Conversations Episode 33 Kentucky has the highest rate of new cancer cases and deaths in the nation, with the greatest burden of the disease being in the Appalachian region. High risk behaviors, poverty, low healthcare access and engagement, and other factors drive these high rates.  This month on Cancer Conversations on Talking FACS, Dr. Nathan Vanderford shares about his second edition book The Cancer Crisis in Appalachia, a collection of essays written by students who have been personally affected by cancer and also live in the region.  We visit with two of these students, Karlee Compton and Michael Buoncristiani, as they share about their experience participating in the ACTION program and writing for the book. Listen to: Karlee's Story Just A Disease Michael's Story A Continuous War   For more information about : Appalachian Career Training in Oncology Program   Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On Twitter @UKMarkey    

In this explosive interview with Dr Mikovits we discuss: viruses vs terrain, truth about vaccines, pharma cult, medical industrial complex, COVID vaccines, vaccine injuries and how to cure, gender confusion, contaminated blood/food supply, the Fauci fraud, the pandemic fraud, and more. Dr Judy Mikovits website: https://therealdrjudy.com/

 Her online health store https://drjsol.gethealthy.store Judy Mikovits, PhD is a biochemist and molecular biologist with more than 35 years of experience. Internationally known, a veritable “rock star” of the scientific world, she served as the director of the lab of Antiviral Drug Mechanisms at the National Cancer Institute before directing the Cancer Biology program at EpiGenX Pharmaceuticals. She later developed the first neuroimmune institute. Her early work focused on cancer and HIV, her latest on Chronic Fatigue Syndrome and autism. She has published more than 50 peer-reviewed articles. My site: https://www.dwtruthwarrior.com Watch the new CULT OF THE MEDICS trailer: https://cultofthemedics.com/ + RISE ATTIRE'S OFFICIAL SIGNATURE SERIES LINE OF APPAREL FOR CULT OF THE MEDICS, BY DW TRUTHWARRIOR + http://riseattireusa.com/cultofthemedics MY SPONSOR: DEFUND VANGUARD stop giving your $ to walmart, make the switch! https://truthwarriorswitch.com/